Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease

C1s antibody prevents Complement-mediated destruction of red blood cells exposed to patient autoantibodies

2014-04-14

(Press-News.org) SOUTH SAN FRANCISCO, Calif.--True North Therapeutics, Inc., announced today a publication demonstrating that the company's C1s antibody prevents the destruction of human red blood cells exposed to plasma samples of patients with a type of autoimmune hemolytic anemia (AIHA). The article entitled "TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinin disease patient autoantibodies" was published on-line in the journal Blood earlier this month. TNT003 is the murine analog of True North's lead humanized monoclonal antibody drug candidate, TNT009, for which the company plans to initiate the first clinical program in 2015.

In ex vivo studies using plasma samples from patients with a type of AIHA known as cold agglutinin disease (CAD), True North demonstrated that red blood cells exposed to patient samples contained high levels of Complement proteins deposited on the cell surface. True North showed that by inhibiting Complement deposition on the red blood cell membrane, TNT003 prevented the red blood cells from being engulfed by macrophages, immune cells responsible for clearing Complement-coated cells and debris from the blood. TNT003 also prevented direct red blood cell lysis driven by a CAD sample that contained unusually high levels of autoantibodies, suggesting that a Complement inhibitor like TNT003 could be efficacious in severe cases of CAD.

"By selectively shutting down the Classical Complement pathway with an antibody, the main drivers of anemia in CAD have been reduced in this preclinical study. Using TNT003 and a large number of 40 patient samples, we were able to deepen the field's understanding of the Complement system's role in this rare disease. The study strengthens the hypothesis that such an approach could be beneficial in this rare patient population," stated Sandip Panicker, PhD, C1s Program Lead and senior author on the journal article in Blood.

TNT003 inhibits C1s, a member of the Complement family of plasma proteins, which, upon activation, trigger a powerful enzymatic cascade that destroys and removes pathogens from the circulation. However, aberrant Complement system activation has been described in numerous autoimmune settings in which antibodies that attack self, known as autoantibodies, play a role in disease pathogenesis. Like other forms of AIHA, CAD is a disorder in which anti-red blood cell antibodies bind to and lead to the destruction of patient red blood cells through Complement system activation.

Dr. Panicker further stated, "As Complement system activity is the only known driver of red blood cell destruction in patients with CAD, the results in the study published in Blood provide compelling evidence for the development of TNT009, the company's lead humanized monoclonal antibody, for the treatment of CAD and potentially other forms of AIHA, for which no approved therapies exist."

INFORMATION: About TNT009

TNT009 is a first-in-class molecule developed to selectively inhibit C1s, a serine protease specific to the Classical Complement pathway of the immune system. By precisely targeting the Classical Complement pathway, TNT009 offers a novel approach for treating Complement-mediated diseases with significant unmet medical needs in the hematologic, renal, and neurological therapeutic areas. With a unique mechanism of action and high target specificity, TNT009 selectively inhibits disease processes in the Classical Complement pathway cascade while maintaining the important immune surveillance provided by the Alternative Complement Pathway and Lectin Complement Pathway. With preclinical and ex vivo data demonstrating TNT009's efficacy, True North Therapeutics anticipates initiating the first clinical program with TNT009 in 2015.

About True North Therapeutics

True North Therapeutics is a biotechnology company developing novel therapies that selectively target the Complement pathway of the immune system to address fundamental mechanisms in diseases with high unmet need, including rare diseases. The company's lead monoclonal antibody drug candidate, TNT009, selectively inhibits a target in the Classical Complement pathway, thereby preventing downstream disease processes involving phagocytosis, inflammation, and cell lysis. True North's drug development programs are focused on Complement-mediated diseases in the hematologic, renal, and neurological therapeutic areas. True North Therapeutics is located in South San Francisco, California. For more information, please visit http://www.truenorthrx.com.

ELSE PRESS RELEASES FROM THIS DATE:

Neuroscientists: Brain activity may mark the beginning of memories

2014-04-14

By tracking brain activity when an animal stops to look around its environment, neuroscientists at the Johns Hopkins University believe they can mark the birth of a memory. Using lab rats on a circular track, James Knierim, professor of neuroscience in the Zanvyl Krieger Mind/Brain Institute at Johns Hopkins, and a team of brain scientists noticed that the rats frequently paused to inspect their environment with head movements as they ran. The scientists found that this behavior activated a place cell in their brain, which helps the animal construct a cognitive map, ...

Piezotronics and piezo-phototronics leading to unprecedented active electronics and optoelectronics

2014-04-14

New technologies for developing electronics and optoelectronics with tunable/adaptive functionalities and performance are critical to emerging applications in wearable technology, communication, pervasive computing, human-machine interfacing and biomedical diagnostics, in which the active and adaptive interactions between devices and stimuli from the ambient/host (e. g. human body) are essential. Mechanical stimuli are ubiquitous and abundant in the environment for interacting with or controlling these electronics/optoelectronics. This is, however, not facile to implement ...

Quantum manipulation: Filling the gap between quantum and classical world

2014-04-14

Quantum superposition is a fundamental and also intriguing property of the quantum world. Because of superposition, a quantum system can be in two different states simultaneously, like a cat that can be both "dead" and "alive" at the same time. However, this anti-intuitive phenomenon cannot be observed directly, because whenever a classical measuring tool touches a quantum system, it immediately collapse into a classical state. On the other hand, quantum superposition is also the core of quantum computer's enormous computational power. A quantum computer can easily break ...

New Commission study identifies Europe's top ICT hubs

2014-04-14

Wondering what makes an ICT hotspot? Take a look at Munich, London, Paris or smaller cities such as Darmstadt identified in a new EU Atlas of ICT hotspots. This atlas shows where digital technologies thrive and examines the factors contributing to this success. Most of Europe's ICT activity takes place in 34 regions across 12 countries (listed in the Annex). Key ingredients to success included access to top Universities and research centres and funding opportunities such as venture capital. European Commission Vice-President @NeelieKroesEU said: "This is proof that ...

Climate change: The role of oceanic carbon reservoir over glacial cycles

2014-04-14

Glacial cycles at 104-yr time scale have been the focus of Quaternary paleoclimatology over the last century. In recent years with the emergence of continuous high-resolution records (ice cores, deep-sea sediments etc.) from the longer geological past, increasing evidence underscores the significance of long- duration processes at the time scale of 105-yr or more. WANG Pinxian and colleagues from the State Key Laboratory of Marine Geology, Tongji University, reviewed long-term variations in the oceanic carbon reservoir and indicated their crucial role in major climate regime ...

Genetically modified tobacco plants as an alternative for producing bioethanol

2014-04-14

Tobacco, a high-density crop which is mown several times throughout its cycle, can produce as much as 160 tonnes of fresh matter per hectare and become a source of biomass suitable for producing bioethanol. As Jon Veramendi, head of the plant Agrobiotechnology research group, explained, "tobacco plants as a source of biomass for producing bioethanol could be an alternative to traditional tobacco growing which is in decline in the USA and in Europe because it cannot compete with emerging countries like China". In the course of the research, which has been echoed by the ...

Puget Sound's rich waters supplied by deep, turbulent canyon

2014-04-14

The headwaters for Puget Sound's famously rich waters lie far below the surface, in a submarine canyon that draws nutrient-rich water up from the deep ocean. New measurements may explain how the Pacific Northwest's inland waters are able to support so many shellfish, salmon runs and even the occasional pod of whales. University of Washington oceanographers made the first detailed measurements at the headwater's source, a submarine canyon offshore from the strait that separates the U.S. and Canada. Observations show water surging up through the canyon and mixing at surprisingly ...

Study links domestic abuse to mental health problems in new mothers

2014-04-14

A new study shows that domestic abuse is closely linked to postpartum mental health problems, including depression and post-traumatic stress disorder (PTSD), in mothers. The research also found that specific types of abuse are associated with specific mental health problems. The work was done by researchers at North Carolina State University, Simon Fraser University and the University of British Columbia. "We wanted to see whether and how intimate partner abuse – physical, psychological and sexual – influenced postpartum mental health in women, including problems such ...

Neanderthals and Cro-magnons did not coincide on the Iberian Peninsula

2014-04-14

This news release is available in Spanish. Until now, the carbon 14 technique, a radioactive isotope which gradually disappears with the passing of time, has been used to date prehistoric remains. When about 40,000 years, in other words approximately the period corresponding to the arrival of the first humans in Europe, have elapsed, the portion that remains is so small that it can become easily contaminated and cause the dates to appear more recent. It was from 2005 onwards that a new technique began to be used; it is the one used to purify the collagen in DNA tests. ...

Let the sun shine in: Redirecting sunlight to urban alleyways

2014-04-14

WASHINGTON, April 14—In dense, urban centers around the world, many people live and work in dim and narrow streets surrounded by tall buildings that block sunlight. And as the global population continues to rise and buildings are jammed closer together, the darkness will only spread. To alleviate the problem, Egyptian researchers have developed a corrugated, translucent panel that redirects sunlight onto narrow streets and alleyways. The panel is mounted on rooftops and hung over the edge at an angle, where it spreads sunlight onto the street below. The researchers describe ...

LAST 30 PRESS RELEASES:

Is eating more red meat bad for your brain?

How does Tourette syndrome differ by sex?

Red meat consumption increases risk of dementia and cognitive decline

Study reveals how sex and racial disparities in weight loss surgery have changed over 20 years

Ultrasound-directed microbubbles could boost immune response against tumours, new Concordia research suggests

In small preliminary study, fearful pet dogs exhibited significantly different microbiomes and metabolic molecules to non-fearful dogs, suggesting the gut-brain axis might be involved in fear behavior

Examination of Large Language Model "red-teaming" defines it as a non-malicious team-effort activity to seek LLMs' limits and identifies 35 different techniques used to test them

Most microplastics in French bottled and tap water are smaller than 20 µm - fine enough to pass into blood and organs, but below the EU-recommended detection limit